Table 1.
General Population Model: Maternal and Infant Characteristics Associated with Neonatal Abstinence Syndrome.
| No Diagnosis of Neonatal Abstinence Syndrome |
Neonatal Abstinence Syndrome | p-value | |
|---|---|---|---|
| N=214812 | N=3208 | ||
| Infant Characteristics | |||
| Birthweight (g), Median (IQR) | 3204 (2870-3535) | 2968 (2620-3289) | <0.001 |
| Gestational Age (weeks), Median (IQR) | 39 (38-40) | 39 (38-40) | <0.001 |
| Small for Gestational Age, % (N) | 18 (38711) | 34 (1078) | <0.001 |
| Female, % (N) | 49 (104908) | 44 (1425) | <0.001 |
| Maternal Characteristics | |||
| Maternal Age, Median (IQR) | 23 (20-27) | 26 (23-29) | <0.001 |
| Hepatitis C Virus Positive, % (N) | 1 (1410) | 15 (480) | <0.001 |
| Medication Exposures in Last 30 Days of Pregnancy | |||
| Immediate-Release Opioid (days), Median (IQR) | 0 (0-0) | 0 (0-0) | <0.001 |
| Sustained-Release Opioid (days), Median (IQR) | 0 (0-0) | 0 (0-0) | <0.001 |
| MOUD (days), Median (IQR) | 0 (0-0) | 0 (0-18) | <0.001 |
| Benzodiazepine, % (N) | 0 (331) | 2 (67) | <0.001 |
| Antipsychotics, % (N) | 0 (739) | 2 (58) | <0.001 |
| SSRI, % (N) | 2 (4338) | 7 (226) | <0.001 |
| Zolpidem, % (N) | 1 (3111) | 2 (76) | <0.001 |
| Bupropion, % (N) | 0 (850) | 2 (57) | <0.001 |
| Reflux and Anti-Nausea, % (N) | 7 (15646) | 15 (481) | <0.001 |
| Number of Cigarettes per Day, Median (IQR) | 0 (0-0) | 8 (0-13) | <0.001 |
*
IQR = Interquartile range
**
Medication data are obtained from filled prescriptions